BioPharma Dive11m
Biohaven muscle drug misses goal of SMA study, but advances in obesity
The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the ...
BioPharma Dive8h
Gene Silencing Technology Unlocks Rapid Weight Loss While Preserving Lean Mass and Preventing Weight Regain
Reduced Weight Regain: CCT-217 shows promise in preventing weight regain commonly observed after discontinuing incretin ...
BioPharma Dive2d
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA
A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the ...
BioPharma Dive2d
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
BioPharma Dive3d
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...
BioPharma Dive3d
Lexicon to disband sales team, lay off 60% of staff
The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application ...
BioPharma Dive3d
Incyte sinks on setback for drugs acquired in $750M buyout
The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...
BioPharma Dive3d
Will Walgreens’ store closures disrupt its clinical trial aims?
Despite plans to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy giant remains committed ...